{"brief_title": "Bupropion for the Treatment of Methamphetamine Dependence - 1", "brief_summary": "The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence", "detailed_description": "A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.", "condition": ["Amphetamine-Related Disorders"], "intervention_type": ["Drug"], "intervention_name": ["Bupropion"], "criteria": "Inclusion Criteria: - Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis - Subject must be willing to comply with study procedures. - Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures - Be able to comply with protocol requirements Exclusion Criteria: - Please contact site for more information.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "amphetamine dependence", "mesh_term": ["Amphetamine-Related Disorders", "Methamphetamine", "Bupropion"], "id": "NCT00069251"}